Barbara Duncan
FINANCE
OVID THERAPEUTICS
New Zealand
Biography
Barbara Duncan, MBA, has served as a member of our board of directors since June 2017. She previously served as the chief financial officer and treasurer at Intercept Pharmaceuticals, Inc. Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including chief financial officer and ultimately serving as chief executive officer prior to DOV’s sale to Euthymics Bioscience, Inc. in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers Inc. She currently serves on the board of Aevi Genomic Medicine, Inc., Jounce Therapeutics, Inc., Adaptimmune Therapeutics plc, Innoviva, Inc. and ObsEva SA. Ms. Duncan received her B.S. from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.
Research Interest
=
